canakinumab

Trials studying canakinumab

• EP1A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinomacompletedn=17
• phase2A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemiarecruitingn=76
• phase3Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDcompletedn=14
• phase3Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjectsterminatedn=673
• —Ilaris NIS in Korearecruitingn=25
• phase2Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAactive not recruitingn=13
• phase2A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)terminatedn=23
• phase2Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Diseaseterminatedn=34